ARK Genomic Revolution ETF (ARKG)
| Assets | $2.58B |
| NAV | $33.66 |
| Expense Ratio | 0.75% |
| PE Ratio | n/a |
| Shares Out | 76.70M |
| Dividend (ttm) | $0.38 |
| Dividend Yield | 1.10% |
| Ex-Dividend Date | Dec 29, 2021 |
| 1-Year Return | -62.69% |
| Volume | 641,846 |
| Open | 44.12 |
| Previous Close | 33.66 |
| Day's Range | 33.01 - 34.64 |
| 52-Week Low | 37.94 |
| 52-Week High | 94.14 |
| Beta | 1.53 |
| Holdings | 49 |
| Inception Date | Oct 31, 2014 |
About ARKG
The fund is an actively-managed exchange-traded fund (ETF) that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution (Genomics Revolution Companies). It is non-diversified.
Top 10 Holdings
47.31% of assets| Name | Symbol | Weight |
|---|---|---|
| Exact Sciences | EXAS | 7.12% |
| Ionis Pharmaceuticals | IONS | 6.56% |
| Teladoc Health | TDOC | 5.19% |
| CRISPR Therapeutics AG | CRSP | 4.84% |
| Signify Health | SGFY | 4.59% |
| Fate Therapeutics | FATE | 4.26% |
| CareDx | CDNA | 3.87% |
| Twist Bioscience | TWST | 3.75% |
| Vertex Pharmaceuticals | VRTX | 3.60% |
| Incyte | INCY | 3.53% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 29, 2021 | $0.38239 | Dec 31, 2021 |
| Dec 29, 2020 | $0.79013 | Dec 31, 2020 |
| Dec 27, 2019 | $1.05395 | Dec 31, 2019 |
| Dec 27, 2018 | $0.46634 | Dec 31, 2018 |
| Dec 27, 2017 | $0.32769000000000004 | Dec 29, 2017 |
News
Get Exposure to the Genomic Revolution With ARKG
Ultima Genomics has claimed that its first instrument, the UG100, will sequence a human genome for under $100. The news surprised and perhaps delighted the life sciences community, as the price to seque...
An Innovative ETF Opportunity That Taps Into Our Increased Understanding of the Human Genome
With a targeted disruptive innovation biotechnology-related exchange traded fund strategy, investors can focus on companies driving change in targeted therapeutics, bioinformatics, CRISPR technology, an...
Change the DNA of Your Portfolio: Growth Opportunities Through Genomics
Thanks to DNA sequencing and the genomic revolution, we could be on the cusp of a brand-new era of healthcare solutions that could extend and enhance the quality of human life. Several key biotech compa...
Cathie Wood Is Selling Gene Editing Stocks. Here's Why.
Cathie Wood has recently sold off large positions in several gene-editing stocks from her ARKG ETF. What's behind Wood's latest moves?
Some ARKG Components Could Lead in Genetic Testing
In the healthcare space, it's often said that an ounce of prevention is worth a pound of cure, and that's undeniably true when it comes to cancer prevention and treatment. A clear avenue for bolstering ...
Ark is Sinking: Can Cathie Wood Bounce Back?
Catherine Wood (Trades, Portfolio) is a growth stock investor who believes disruptive innovation and technology are the keys to great investing returns. Her firm's flagship fund, the Ark Innovation ETF ...
ARK Crushed By Concentrated Bet In Teladoc
Shares of the telemedicine provider were cut in half on Thursday, pressuring ARKK and other ETFs.
Why Investors Should Consider ETFs That Target Innovation Platforms
Investors should keep an eye on innovative platforms-related exchange traded funds to capture tomorrow's growth ideas today. In the recent webcast, Refining Your Innovation Exposure: How to Access Tomor...
Refining Your Innovation Exposure: How to Access Tomorrow's Opportunities
ARK's research identifies five innovation platforms that are evolving simultaneously, transforming the world around us. These platforms are Artificial Intelligence (AI), Blockchain Technology, Energy St...
Cathie Wood Snaps Back At Critics, Predicts 50% Annual Returns
The ARK CEO remains steadfast in her belief that her exchange-traded funds will outperform again.
In Genomics, Tech Matters
Genomics has long been one of the more tech-centric corners of the healthcare space, and that remains the case today. That's a strong indication that disruptive technologies often intersect with and dep...
Disruptive Tech ETFs Rally on Encouraging Dialogue Between Russia and Ukraine
Disruptive technology-related exchange traded funds rallied on Tuesday as U.S. markets turned risk-on, following positive updates on Russia and Ukraine's negotiations. Among the best-performing non-leve...
Invest in Next-Gen Technologies With These 2 ETFs
These funds focus on revolutions in healthcare and technology.
Teladoc Endorsement Could Be Positive for This ETF
Healthcare innovation equities are languishing, but it could time for one of the most well-known names in the group to turn around, and that could be constructive for select exchange traded funds, inclu...
Ark is Sinking - Will Ark Invest Recover?
Catherine Wood (Trades, Portfolio) (Trades, Portfolio) is a growth stock investor who believes innovation and technology are the keys to great investing returns. Her flagship fund, the Ark Innovation ET...
Volatility Is Not a Bad Word With a Long-Term Time Horizon
While disruptive innovation strategies may experience short-term volatility, ARK's research shows that maintaining a long-term investment time horizon is critical for investors searching for potential r...
A Bright Outlook for Gene Editing Investing
With biotechnology stocks, particularly those in mid- and small-cap territory, heavily out of favor at the moment, it's not surprising that some investors are ignoring genomics assets. That sentiment be...
Cathie Wood Explains Why Ark Investment Sends A Daily Email Disclosing Stock Moves
Every night, an email comes out from Ark Investment Management highlighting the stocks that were bought or sold by the firm's ETFs. In recent months, the emails have been known to cause certain stocks t...
Gene Editing Stocks Might Be Building Some Momentum
Experienced healthcare and biotechnology investors know that January brings the arrival of the widely followed JPMorgan healthcare conference. This year, it's taking place in virtual fashion, but that's...
Pfizer/Beam Deal Highlights In Vivo Potential
It's just one deal, but genomics companies with exposure to in vivo gene editing may be getting a much-needed boost after blue-chip pharmaceuticals company Pfizer (NYSE:PFE) announced a related agreemen...
Yield Spikes Muddy ARK's Waters
Cathie Wood's multibillion-dollar funds are off to a rocky start in 2022.
Should You Bet on Cathie Wood in 2022?
Two of ARK Invest's most popular ETFs were down double digits in 2021. Is it time to buy?
CRISPR Could Come Alive in 2022
Clustered regularly interspaced short palindromic repeats, colloquially known as CRISPR, is one of the bedrocks of the genomics investment thesis, and it could be poised for big things in 2022. If that'...